The chronic insomnia market offers some important lessons for pharma companies when it comes to digital therapeutics.
This article describes how three very similar digital therapeutics (DTx) with divergent pricing and business models are targeting chronic insomnia. It also outlines the implications for pharma companies that are considering a move into DTx, as well as some keys to success.
